Evotec
Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.
Latest Content
Evotec Announces Key Progress in Neuroscience Collaboration With Bristol Myers Squibb
The Promise of Continuous Processing To Advance Biopharmaceutical Production
Innovations in Biopharma 2025
Evotec Receives Grant From Korean Government To Develop Novel Antibody-Based Treatments for Lung Diseases
Evotec SE Announces First Projects for LAB eN² Drug Discovery Accelerator With Novo Nordisk
Spatial Transcriptomics in Neuroscience
Harnessing Structural Insights in Drug Discovery
Therapeutic siRNAs: Considerations for “Picking the Best One”
Trends in Target-Based Drug Discovery